Durvalumab plus a fixed dose of tremelimumab [1 mg/kg every 4 weeks (Q4W)] for R/M HNSCC produced an objective response rate (ORR) of 7.8% among patients with PD-L1 TC <25% in the CONDOR study.12 Here, CD274 is linked to head and neck squamous cell carcinoma.